References
- 1.ZHANG G L, GAO Z L. The immunological characteristics of and treatment strategies for HBV related acute-on-chronic liver failure[J]. Chin J Viral Dis, 2011, 1(1): 5-8.
- 2.YE Y N, GAO Z L.Three attacks in the development of HBV-related liver failure[J]. Chin J Hepatol, 2009, 17(7): 638-640.
- 3.RUESCHENBAUM S, CIESEK S, QUECK A, et al. Dysregulated adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure[J]. Front Immunol, 2021, 11:534731.
- 4.MUÑOZ-ROJAS A R, MATHIS D. Tissue regulatory T cells: Regulatory chameleons[J]. Nat Rev Immunol, 2021, 21(9): 597-611.
- 5.LI J, LIANG X, JIANG J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2021, 71(1): 163-175.
- 6.NORLANDER A E, BLOODWORTH M H, TOKI S, et al. Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming[J]. J Clin Invest, 2021, 131(7): e140690.
- 7.IANNACONE M, GUIDOTTI LG. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2021, 22(1): 19-32.
- 8.JENG W J, PAPATHEODORIDIS G V, LOK A S F. Hepatitis B[J]. Lancet, 2023, 401(10381): 1039-1052.
- 9.HOOGEVEEN R C, DIJKSTRA S, BARTSCH L M, et al. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+ infection[J]. J Hepatol, 2022, 77(5): 1276-1286.
- 10.TAN N H, CHEN B, PENG J, et al. Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages[J]. Bio Med Res Int, 2021, 2021: 1-13.
- 11.CHEN B, DING X L, PENG J, et al. Effect of warming and heat-clearing method on expressions of FoxP3 and ROR-γt in colon tissue of rats with intestinal endotoxemia caused by acute-on-chronic liver failure[J]. Chin J Exp Tradit Med Form, 2020, 26(2): 19-25.
- 12.QIN C. Laboratory animal science[M]. Beijing: People's Health Publishing House, 2010: 420.
- 13.MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease:Acute-on-chronic liver failure, a systematic review and Meta-analysis[J]. Gut, 2021, 71(1): 148-155.
- 14.JIA G H, YOU J, LI J, et al. ole of FoxP3/Treg and RORγt/Th17 imbalance in chronic hepatitis B virus infection[J]. World Chin J Dig, 2019, 27(11): 709-714.
- 15.XU R Z, LI Y. On the relationship between Fuzheng Quxie therapy and immunity in traditional Chinese medicine for cancer treatment[J]. Liaoning J Tradit Chin Med, 2018, 45(9): 1858-1859.
- 16.YANG L H, HU K W, WANG J X. Mechanism of therapeutic methods of activating blood,resolving phlegm, and removing toxins in liver cancer based on immune microenvironment[J]. Chin J Exp Tradit Med Form, 2022, 28(14): 172-178.
- 17.LONG F L, CHEN X M, WANG N, et al. Prognostic intervention of Jiedu Huayu granules in acute-on-chronic liver failure: A study based on IL-17 expression proportion in CD4+ T cells[J]. Lishizhen Med Mater Med Res, 2017, 28(4): 796-798.
- 18.LIAN Y N. The correlation between frequency of peripheral blood T lymphocytes and prognosis of patients with HBV-ACLF and the immunological mechanism of the treatment by principle of strengthening vital Qi and the spleen based on the deficiency in vital Qi[D]. Nanjing: Nanjing University of Chinese Medicine, 2016.
- 19.BAI W J, MAO D W, SHI Q L, et al.Effect of Jiedu Huayu granules on inflammatory state of patients with chronic hepatic failure with toxic heat and stasis syndrome[J]. Chin J Exp Tradit Med Form, 2022, 28(3): 109-115.
- 20.PENG J, CHEN B, SUN K W, et al. Retrospective analysis of distribution and evolution characteristics of syndrome dampness heat-blood stasis-spleen deficiency of chronic severe hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2011, 21(3): 135-138.
- 21.SUN K W, CHEN B, HUANG Y H, et al. Clinical characteristics of icterus in patients with chronic severe hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2010, 20(1): 8-11.
- 22.SONG Z F, PENG J, CHEN B, et al. Effects of clearing and warming method on the expression of Treg/Th17 cytokine in HBV-ACLF patients with non-syndrome of yang jaundice[J]. China J Tradit Chin Med Pharm, 2018, 33(12): 5687-5691.
- 23.CHEN B, LI Y F, ZHANG T, et al. Effects of clearing and warming method on expression of Treg/Th17 related cytokines and transcription factors in rats with acute-on-chronic liver failure[J]. China J Tradit Chin Med Pharm, 2020, 35(9): 4618-4622.
- 24.CHEN B, PENG J, ZHANG T, et al. Effects of clearing and warming simultaneously on colonic regulatory T lymphocytes assistant T lymphocyte 17 cytokines in rats with acute and chronic liver failure[J]. J Hunan Univ Chin Med, 2019, 39(5): 573-577.
- 25.BONELLI M, GÖSCHL L, BLÜML S, et al. CD4⁺CD25⁻Foxp3⁺T cells: A marker for lupus nephritis? [J]. Arthritis Res Ther, 2014, 16(2): R104.
- 26.KIM J, HOPE C M, PERKINS G B, et al. Rapamycin and abundant TCR stimulation are required for the generation of stable human induced regulatory T cells[J]. Clin Transl Immunol, 2020, 9(12): e1223.
- 27.SAHIN M, SAHIN E. Prostaglandin E2 reverses the effects of DNA methyltransferase inhibitor and TGF-β1 on the conversion of naive T cells to iTregs[J]. Transfus Med Hemother, 2020, 47(3): 244-253.
- 28.CHEN X, FENG L, LI S, et al. TGF-β1 maintains FoxP3 expression and inhibits glycolysis in natural regulatory T cells via PP2A-mediated suppression of mTOR signaling[J]. Immunol Lett, 2020, 226: 31-37.
- 29.SCHMIDT A, ÉLIÁS S, JOSHI RN, et al. In vitro differentiation of Human CD4+FOXP3f induced regulatory T cells(iTregs)from naïve CD4+ T cells using a TGF-β- containing protocol[J]. J Vis Exp, 2016, 30(118): 55015.
- 30.YANG J, WEI P, BARBI J, et al. The deubiquitinase USP44 promotes Treg function during inflammation by preventing FoxP3 degradation[J]. EMBO Rep, 2020, 21(9): e50308.
- 31.HOU P F, ZHU L J, CHEN X Y, et al. Age-related changes in CD4+CD25+FoxP3+ regulatory T cells and their relationship with lung cancer[J]. PLoS One, 2017, 12(3): e0173048.
- 32.VITALES-NOYOLA M, LAYSECA-ESPINOSA E, BARANDA L, et al. Analysis of sodium chloride intake and Treg/Th17 lymphocytes in healthy individuals and patients with rheumatoid arthritis or systemic lupus erythematosus[J]. J Immunol Res, 2018, 2018: 9627806.
- 33.BRINKHOFF A, SIEBERICHS A, ENGLER H, et al. Pro-inflammatory Th1 and Th17 cells are suppressed during human experimental endotoxemia whereas anti-inflammatory IL-10 producing T-cells are unaffected[J]. Front Immunol, 2018, 9: 1133.
- 34.PATRIZIA F, MARTIN S, WINFRIED G, et al. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders[J]. Molecules, 2017, 22(1): 134.
- 35.SINGH R P, HASAN S, SHARMA S, et al. Th17 cells in inflammation and autoimmunity[J]. Autoimmu Rev, 2014, 13(12): 1174-1181.
- 36.LIM H W, LEE J, HILLSAMER P, et al. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FoxP3+ regulatory T cells[J]. J Immunol, 2008, 180(1): 122-129.


